A predictive model for low-dose rituximab response in anti-acetylcholine receptor antibody-positive myasthenia gravis: establishment and validation
{{output}}
Background: Rituximab (RTX) represents an established therapeutic option for myasthenia gravis refractory to conventional immunotherapy. However, its heterogeneous efficacy across populations creates a challenge in clinical appli... ...
